# Rheumatoid Arthritis - Biologics and Targeted Therapies

## Introduction

Biologic disease-modifying antirheumatic drugs (bDMARDs) and targeted synthetic DMARDs (tsDMARDs) have fundamentally transformed the outcomes of rheumatoid arthritis since the approval of infliximab in 1999. Current guidelines from both the ACR and EULAR recommend escalation to a bDMARD or tsDMARD after an inadequate response to conventional synthetic DMARDs, typically methotrexate. No head-to-head studies have demonstrated superiority of one TNF inhibitor over another, and treatment selection is guided by patient-specific factors including comorbidities, route of administration preferences, and reproductive planning. The advent of biosimilars has substantially increased access and reduced the cost of biologic therapy, further broadening the reach of these transformative agents.

## TNF Inhibitors

### Mechanism and Pharmacology

Tumor necrosis factor-alpha is a key pro-inflammatory cytokine produced by macrophages, T cells, and fibroblast-like synoviocytes that plays a central role in synovial inflammation, osteoclast activation, and joint destruction. Both membrane-bound and soluble forms of TNF contribute to the pathogenic inflammatory cascade in the rheumatoid joint. Five TNF inhibitors are currently approved for the treatment of RA: infliximab, etanercept, adalimumab, certolizumab pegol, and golimumab. Although all target TNF-alpha, these agents differ in their molecular structure, route of administration, dosing schedule, and certain clinical properties that influence their selection in specific clinical scenarios.

### Individual Agents

Infliximab is a chimeric IgG1 monoclonal antibody administered intravenously at a dose of 3 milligrams per kilogram at weeks zero, two, and six, followed by every eight weeks, with the option to escalate to 10 milligrams per kilogram or increase frequency to every four weeks in patients with inadequate response. The pivotal ATTRACT trial established the superiority of infliximab plus methotrexate over methotrexate alone. Etanercept, a soluble TNF receptor (p75)-Fc fusion protein, is administered subcutaneously at 50 milligrams weekly or 25 milligrams twice weekly. The TEMPO trial demonstrated the superiority of combination etanercept plus methotrexate over either agent alone. A critical clinical distinction is that etanercept, as a fusion protein rather than a monoclonal antibody, does not effectively treat granulomatous diseases such as Crohn's disease or sarcoidosis.

Adalimumab, a fully human IgG1 monoclonal antibody, is administered subcutaneously at 40 milligrams every two weeks, with the PREMIER trial demonstrating superiority of combination therapy over monotherapy at two years. Certolizumab pegol is unique among the TNF inhibitors in that it is a PEGylated Fab' fragment lacking an Fc region. This structural feature is clinically significant because it means certolizumab does not cross the placenta, making it the preferred TNF inhibitor during pregnancy. It is administered subcutaneously at 400 milligrams at weeks zero, two, and four, followed by 200 milligrams every two weeks, as established in the RAPID trials. Golimumab, a fully human IgG1 monoclonal antibody, is administered subcutaneously at 50 milligrams monthly or intravenously at 2 milligrams per kilogram, as studied in the GO-FORWARD trial.

| Agent | Structure | Route | Dosing | Key Trial | Placental Transfer | Unique Feature |
|-------|-----------|-------|--------|-----------|-------------------|----------------|
| Infliximab | Chimeric IgG1 mAb | IV | 3 mg/kg wks 0, 2, 6 then q8wk | ATTRACT | Yes | Dose escalation possible; chimeric → higher immunogenicity |
| Etanercept | Soluble TNF receptor-Fc fusion | SC | 50 mg weekly | TEMPO | Yes | **Does not treat granulomatous disease** (Crohn's, sarcoidosis) |
| Adalimumab | Fully human IgG1 mAb | SC | 40 mg q2wk | PREMIER | Yes | First fully human TNFi; most biosimilars available |
| Certolizumab pegol | PEGylated Fab' fragment (no Fc) | SC | 400 mg wks 0, 2, 4 then 200 mg q2wk | RAPID 1/2 | **No** (no Fc region) | **Preferred in pregnancy** |
| Golimumab | Fully human IgG1 mAb | SC or IV | SC 50 mg monthly; IV 2 mg/kg | GO-FORWARD | Yes | Monthly SC dosing convenience |

| Non-TNF Biologic | Target | Route/Dose | Key Trial | Monotherapy Efficacy | Unique Consideration |
|------------------|--------|------------|-----------|---------------------|---------------------|
| Tocilizumab | IL-6 receptor | IV 4–8 mg/kg q4wk or SC 162 mg weekly | AMBITION | **Superior to MTX monotherapy** | CRP unreliable for monitoring; GI perforation risk |
| Sarilumab | IL-6 receptor | SC 200 mg q2wk | MONARCH | Superior to adalimumab monotherapy | Fully human mAb |
| Abatacept | CD80/CD86 (T-cell co-stimulation) | IV 500–1000 mg q4wk or SC 125 mg weekly | AGREE, AMPLE | Comparable to adalimumab | Lower infection risk; may be preferred in COPD; anti-CCP+ may respond better |
| Rituximab | CD20 (B cells) | IV 1000 mg days 1 and 15, q6mo | REFLEX | Less effective than other bDMARDs as monotherapy | Most effective in RF+/anti-CCP+ patients; monitor IgG levels |

### Key Trial Data

The pivotal clinical trial programs for the TNF inhibitors collectively established several key principles. The ATTRACT trial demonstrated that infliximab plus methotrexate was superior to methotrexate alone, with significant reduction in radiographic progression. The TEMPO trial showed that etanercept plus methotrexate was superior to either agent alone. The PREMIER trial confirmed the superiority of adalimumab plus methotrexate over either monotherapy at two years. The AMPLE trial, which compared abatacept and adalimumab (both in combination with methotrexate), demonstrated comparable efficacy and safety at two years, providing important evidence that non-TNF biologics are viable alternatives to TNF inhibitors.

A consistent finding across these trials is that most TNF inhibitors are more effective when combined with methotrexate than when used as monotherapy. Methotrexate co-administration reduces the formation of anti-drug antibodies and improves the pharmacokinetics of monoclonal antibody-based TNF inhibitors, resulting in enhanced efficacy and sustained drug levels.

### TNFi Failure

When a patient fails to respond to a TNF inhibitor, it is important to distinguish between primary non-response and secondary failure. Primary non-response, defined as failure to achieve a meaningful clinical improvement with initial therapy, suggests that TNF may not be the dominant pathogenic cytokine in that patient, and a switch to an alternative mechanism of action is generally preferred. Secondary failure, characterized by initial response followed by loss of efficacy over time, is often driven by the development of anti-drug antibodies (ADAs), and patients may respond to switching within the TNF inhibitor class or to a different biologic mechanism. The EXXELERATE trial demonstrated similar response rates with certolizumab and adalimumab, confirming that no single TNF inhibitor is consistently superior to another as a first-line biologic.

<image>A detailed comparison chart of the five TNF inhibitors used in rheumatoid arthritis. For each drug (infliximab, etanercept, adalimumab, certolizumab pegol, golimumab), show: molecular structure (chimeric mAb, fusion protein, human mAb, PEGylated Fab', human mAb), route of administration (IV or SC), dosing schedule, key trial name, whether it crosses the placenta (yes/no), and unique properties. Include small schematic diagrams of each molecule showing their structural differences (Fab, Fc, PEG, receptor portions). Use a clean table format with molecular diagrams.</image>

## Non-TNF Biologics

### IL-6 Receptor Inhibitors

Tocilizumab, a humanized monoclonal antibody targeting the IL-6 receptor, is administered intravenously at 4 to 8 milligrams per kilogram every four weeks or subcutaneously at 162 milligrams weekly. The AMBITION trial was a landmark study demonstrating that tocilizumab monotherapy was superior to methotrexate monotherapy, establishing IL-6 receptor inhibition as one of the few biologic mechanisms effective as monotherapy without methotrexate co-administration. Several important monitoring considerations apply to tocilizumab use. Neutropenia and hepatotoxicity require regular laboratory surveillance. Lipid elevations occur and should be monitored. The risk of gastrointestinal perforation is increased, particularly in patients with diverticular disease. Critically, tocilizumab suppresses CRP production independently of its effect on disease activity, rendering CRP unreliable as a marker of disease control or infection in patients receiving this therapy.

Sarilumab, a fully human monoclonal antibody against the IL-6 receptor, is administered subcutaneously at 200 milligrams every two weeks. The MONARCH trial demonstrated that sarilumab monotherapy was superior to adalimumab monotherapy, further reinforcing the unique effectiveness of IL-6 receptor inhibitors as monotherapy agents.

### T Cell Co-stimulation Blocker

Abatacept is a CTLA-4-immunoglobulin fusion protein that blocks the CD80/CD86-CD28 co-stimulatory interaction required for full T cell activation. It is administered intravenously at weight-based doses of 500 to 1000 milligrams every four weeks or subcutaneously at 125 milligrams weekly. The AGREE trial demonstrated that abatacept plus methotrexate in methotrexate-naive early RA achieved sustained remission. The AMPLE trial established non-inferiority of abatacept to adalimumab, both in combination with methotrexate. Abatacept has a favorable safety profile with lower infection risk compared to other biologic mechanisms and may be preferred in patients with chronic obstructive pulmonary disease, where it carries a lower risk of respiratory infections than TNF inhibitors. Subanalysis of the AVERT trial suggested that anti-CCP-positive patients may respond preferentially to abatacept, reflecting the mechanism's upstream blockade of the T cell-dependent autoimmune response.

### B Cell Depletion

Rituximab, a chimeric anti-CD20 monoclonal antibody, is administered intravenously at 1000 milligrams on day one and day fifteen, with cycles repeated every six months as needed. The REFLEX trial established the efficacy of rituximab plus methotrexate in patients who had failed TNF inhibitor therapy. Rituximab is most effective in patients who are RF-positive and/or anti-CCP-positive, and these serologic markers serve as predictors of response. Pre-medication with intravenous methylprednisolone at 100 milligrams, acetaminophen, and diphenhydramine is standard to reduce infusion reactions.

Rituximab achieves incomplete B cell depletion in tissue compartments, and long-lived plasma cells in bone marrow niches survive anti-CD20 depletion, explaining why autoantibody levels may persist despite effective peripheral B cell depletion. Important monitoring considerations include hypogammaglobulinemia, which increases infection risk and should be assessed by measuring IgG levels, hepatitis B reactivation risk, and the rare but serious complication of progressive multifocal leukoencephalopathy (PML). In the context of COVID-19 and other vaccine-preventable diseases, rituximab's impact on vaccine response requires careful timing of vaccination around treatment cycles.

### IL-1 Inhibition

Anakinra, an IL-1 receptor antagonist administered subcutaneously at 100 milligrams daily, was one of the earliest targeted therapies for RA but has proven less effective than TNF inhibitors for this indication. Its primary role has shifted to other conditions including adult-onset Still disease, gout flares, cryopyrin-associated periodic syndromes, and recurrent pericarditis. The short half-life of four to six hours provides a rapid offset of immunosuppression that is advantageous in clinical situations involving diagnostic uncertainty, where the clinician may want the option to quickly restore immune function.

## Targeted Synthetic DMARDs (tsDMARDs)

### JAK Inhibitors

The Janus kinase inhibitors represent a class of orally administered small molecules that have expanded the therapeutic armamentarium for RA. Tofacitinib, a JAK1/3 inhibitor administered at 5 milligrams twice daily or 11 milligrams extended-release daily, was studied in the ORAL trials program and demonstrated efficacy in both methotrexate-inadequate responders and TNF inhibitor-inadequate responders. The ORAL Surveillance trial, a large post-marketing safety study, revealed higher rates of major adverse cardiovascular events (MACE) and malignancy, particularly lung cancer, in patients aged fifty or older with at least one cardiovascular risk factor, compared to TNF inhibitor therapy. This safety signal has had a profound impact on treatment algorithms.

Baricitinib, a JAK1/2 inhibitor, is administered at 2 milligrams daily in the United States and 4 milligrams daily in Europe, with the option to step down to 2 milligrams. The RA-BEAM trial demonstrated that baricitinib 4 milligrams plus methotrexate was superior to both adalimumab plus methotrexate and methotrexate alone. Upadacitinib, a JAK1-selective inhibitor administered at 15 milligrams daily, demonstrated superiority to adalimumab in the SELECT-COMPARE trial and achieved high remission rates. The SELECT-CHOICE trial showed upadacitinib was superior to abatacept in TNF inhibitor-inadequate responder RA.

All JAK inhibitors carry FDA black box warnings for serious infections, MACE, venous thromboembolism, malignancy, and mortality. The 2022 ACR guidelines conditionally recommend JAK inhibitors after TNF inhibitor failure rather than as first-line bDMARD/tsDMARD therapy, reflecting the safety concerns raised by the ORAL Surveillance trial. Venous thromboembolism risk, including deep vein thrombosis and pulmonary embolism, requires clinical vigilance. Herpes zoster reactivation is a recognized complication, and Shingrix vaccination should be considered before initiating JAK inhibitor therapy.

<image>A mechanism of action diagram showing the JAK-STAT signaling pathway in a cell membrane cross-section. Depict a cytokine receptor dimer with JAK proteins (JAK1, JAK2, JAK3, TYK2) associated with intracellular domains. Show the signaling cascade: cytokine binding → JAK phosphorylation → STAT recruitment and phosphorylation → STAT dimerization → nuclear translocation → gene transcription. Indicate which JAK pairs are used by key cytokines (IL-6 uses JAK1/JAK2/TYK2, gamma-chain cytokines use JAK1/JAK3). Mark the points of inhibition for tofacitinib (JAK1/3), baricitinib (JAK1/2), and upadacitinib (JAK1) with red X symbols and drug names.</image>

## Biosimilars

### Regulatory Framework

Biosimilars are biologic products that are highly similar to an approved reference product with no clinically meaningful differences in safety, purity, or potency. An interchangeable biosimilar meets a higher regulatory standard, allowing substitution at the pharmacy level without prescriber intervention. The FDA requires analytical, animal, and clinical studies demonstrating biosimilarity, including comparative pharmacokinetic, efficacy, and immunogenicity assessments.

### Available Biosimilars in Rheumatology

The biosimilar landscape in rheumatology has expanded considerably. Multiple infliximab biosimilars are available, including CT-P13 (Inflectra/Remsima), SB2 (Renflexis), and infliximab-axxq (Avsola). The NOR-SWITCH trial, a landmark non-inferiority study, demonstrated that switching from originator infliximab to CT-P13 was non-inferior across multiple inflammatory diseases. Numerous adalimumab biosimilars have been approved, and etanercept biosimilars including SB4 (Erelzi) and GP2015 (Eticovo) are available. Rituximab biosimilars include CT-P10 (Truxima), rituximab-pvvr (Ruxience), and rituximab-arrx (Riabni).

### Clinical Considerations

The nocebo effect, in which up to 13 percent of patients switched from originator to biosimilar report subjective worsening despite pharmacologic equivalence, is a recognized clinical challenge that requires careful patient communication and education. Cost savings of 15 to 40 percent compared to originator biologics represent an important benefit of biosimilar adoption. Large registry data have not identified additional safety signals with biosimilar use beyond those already known for the reference products.

## Treatment Algorithms and Sequencing

### 2022 ACR Guidelines Key Recommendations

The 2022 ACR guidelines establish a clear treatment hierarchy for RA. Methotrexate monotherapy is strongly recommended as first-line DMARD therapy. For patients with an inadequate response to methotrexate, the addition of a bDMARD or tsDMARD is conditionally recommended. A TNF inhibitor or non-TNF biologic is conditionally recommended over a JAK inhibitor as the first bDMARD/tsDMARD, reflecting the safety concerns identified in the ORAL Surveillance trial. After TNF inhibitor failure, options include switching to a different TNF inhibitor, a non-TNF biologic, or a JAK inhibitor. Combination with methotrexate is preferred over biologic monotherapy. When biologic monotherapy is necessary, IL-6 receptor inhibitors or JAK inhibitors are preferred over other mechanisms based on their established monotherapy efficacy.

### EULAR 2022 Recommendations

The EULAR 2022 recommendations follow a phased approach. Phase I involves methotrexate at a target dose of 25 milligrams per week, with or without short-term glucocorticoid bridging. Phase II, initiated at three to six months if the target is not achieved, involves the addition of a bDMARD or JAK inhibitor, with any biologic mechanism acceptable as first-line. Phase III, for patients failing Phase II, involves switching to an alternative mechanism of action. Rituximab is specifically preferred in patients with a history of prior lymphoma or in those with latent tuberculosis when chemoprophylaxis is contraindicated.

### Tapering and Discontinuation

The question of whether biologic therapy can be safely tapered or discontinued in patients achieving sustained remission is of great clinical and practical importance. The RETRO trial demonstrated that DMARD dose reduction is feasible in patients with sustained remission, with approximately 50 percent maintaining remission. The PRIZE trial showed that etanercept could be tapered in many patients who achieved remission with etanercept plus methotrexate. However, the AVERT trial found that abatacept withdrawal led to flare in the majority of patients, with only approximately 15 percent maintaining sustained remission. The ACR recommends tapering biologic therapy before conventional DMARDs and continuing csDMARDs longer. Flare risk ranges from 50 to 80 percent within one year of biologic discontinuation, with higher risk in patients who are RF-positive or anti-CCP-positive.

## Special Populations

Several clinical scenarios require specific biologic selection considerations. In patients with hepatitis B, entecavir prophylaxis should be administered with rituximab and TNF inhibitors, and rituximab should be avoided in active HBV infection. In hepatitis C, TNF inhibitors and rituximab are generally safe, but coordination with hepatology for direct-acting antiviral therapy is essential. TNF inhibitors are contraindicated in patients with heart failure (NYHA class III/IV), as the ATTACH and RENEWAL trials demonstrated worsened heart failure outcomes. In patients with a history of demyelinating disease, TNF inhibitors should be avoided and non-TNF biologics should be considered. For patients with a prior malignancy, an individualized risk-benefit assessment is required, and rituximab or abatacept may be preferred based on their safety profiles.

## Key Clinical Pearls

- Etanercept (fusion protein) does not treat granulomatous diseases and is less effective for IBD-associated arthritis
- Certolizumab pegol does not cross the placenta and is the preferred biologic in pregnancy
- Tocilizumab and sarilumab suppress CRP regardless of disease control; use clinical assessment (joint counts, CDAI) for monitoring
- ORAL Surveillance trial shifted guidelines to recommend TNFi/non-TNF bDMARDs before JAKi
- Always combine TNFi with MTX when possible to reduce immunogenicity and improve efficacy
- Rituximab is most effective in seropositive (RF+ or anti-CCP+) RA patients

<image>A treatment algorithm flowchart for rheumatoid arthritis following current ACR/EULAR guidelines. Start with "RA diagnosis confirmed" → MTX 15-25 mg/week + folic acid ± GC bridge therapy. At 3-month reassessment, branch to "Target achieved" (continue, monitor q3-6 months) and "Target not achieved." The not-at-target branch should show options: add TNFi (infliximab, etanercept, adalimumab, certolizumab, golimumab), non-TNF biologic (tocilizumab, abatacept, rituximab, sarilumab), or JAKi (tofacitinib, baricitinib, upadacitinib) with a note that JAKi is conditionally recommended after bDMARD failure. Show a second failure branch leading to mechanism switch. Include comorbidity-based decision boxes (e.g., CHF → avoid TNFi, pregnancy → certolizumab, latent TB → avoid TNFi or use with prophylaxis).</image>

## References
1. Fraenkel L, et al. 2021 American College of Rheumatology Guideline for the Treatment of Rheumatoid Arthritis. Arthritis Care Res. 2021;73(7):924-939.
2. Ytterberg SR, et al. Cardiovascular and cancer risk with tofacitinib in rheumatoid arthritis. N Engl J Med. 2022;386(4):316-326.
3. Fleischmann R, et al. Baricitinib, methotrexate, or combination in patients with RA (RA-BEAM). N Engl J Med. 2017;376(7):652-662.
4. Rubbert-Roth A, et al. Trial of upadacitinib or abatacept in rheumatoid arthritis (SELECT-CHOICE). N Engl J Med. 2020;383:1511-1521.
5. Jorgensen KK, et al. Switching from originator infliximab to biosimilar CT-P13 (NOR-SWITCH). Lancet. 2017;389(10086):2304-2316.